TITLE: Glucose Replacement Agents in Frail Elderly Patients with Type II Diabetes in Long-Term Care: Clinical and Cost-Effectiveness, Harms, and Guidelines

DATE: 13 January 2015

RESEARCH QUESTIONS

1. What is the clinical effectiveness of glucose replacement agents in frail elderly patients with type II diabetes who reside in long-term care (LTC) facilities?

2. What are the harms associated with glucose replacement agents in frail elderly patients with type II diabetes who reside in LTC facilities?

3. What is the cost-effectiveness of using glucose replacement agents in frail elderly patients with type II diabetes who reside in LTC facilities?

4. What are the evidence-based guidelines regarding the use of glucose replacement agents in frail elderly patients with type II diabetes who reside in LTC facilities?

KEY FINDINGS

No health technology assessment reports, systematic reviews, meta-analyses, randomized controlled trials, non-randomized studies, economic evaluations, or evidence-based guidelines were identified regarding glucose replacement agents in frail elderly patients with type II diabetes who reside in long-term care facilities.

METHODS

A limited literature search was conducted on key resources including PubMed, The Cochrane Library (2015, Issue 1), University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. No filters were applied to limit the retrieval by study type. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 1, 2010 and January 5, 2015. Internet links were provided, where available.
The summary of findings was prepared from the abstracts of the relevant information. Please note that data contained in abstracts may not always be an accurate reflection of the data contained within the full article.

**SELECTION CRITERIA**

One reviewer screened citations and selected studies based on the inclusion criteria presented in Table 1.

<table>
<thead>
<tr>
<th>Table 1: Selection Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Population</strong></td>
</tr>
<tr>
<td><strong>Intervention</strong></td>
</tr>
<tr>
<td><strong>Comparator</strong></td>
</tr>
<tr>
<td><strong>Outcomes</strong></td>
</tr>
<tr>
<td><strong>Study Designs</strong></td>
</tr>
</tbody>
</table>

**RESULTS**

No health technology assessment reports, systematic reviews, meta-analyses, randomized controlled trials, non-randomized studies, economic evaluations, or evidence-based guidelines were identified regarding glucose replacement agents in frail elderly patients with type II diabetes who reside in long-term care facilities.

References of potential interest are provided in the appendix.

**OVERALL SUMMARY OF FINDINGS**

No relevant literature was found regarding glucose replacement agents in frail elderly patients with type II diabetes who reside in long-term care facilities; therefore, no summary can be provided.
REFERENCES SUMMARIZED

Health Technology Assessments
No literature identified

Systematic Reviews and Meta-analyses
No literature identified.

Randomized Controlled Trials
No literature identified

Non-Randomized Studies
No literature identified

Economic Evaluations
No literature identified

Guidelines and Recommendations
No literature identified

PREPARED BY:
Canadian Agency for Drugs and Technologies in Health
Tel: 1-866-898-8439
www.cadth.ca
APPENDIX – FURTHER INFORMATION:

Clinical Practice Guidelines – Methodology Unknown

See: Managing diabetes – low blood sugar (hypoglycemia), page 20

See: Algorithm for Management of Hypoglycemia and Hypoglycemia Treatment Kit, pages 17 – 21


See: Treatment of hypoglycaemia, page 22

Review Articles


Additional References

PubMed: PM22586198